What is the evidence for moderate-dose statin safety in patients with CVD?
Most feel the benefits of statins outweigh the risks in patients at risk for CVD. A systematic review by Chou et al. (2016) of primary prevention RCTs reporting statin-induced adverse events showed no increased risk for new-onset diabetes in patients treated with moderate-dose statins versus placebo (relative risk [RR]: 1.05, 95% CI: 0.91 1.2).